Sugi Predict

Sugi Predict / Compounds / SCHEMBL7188161

SCHEMBL7188161

SCHEMBL7188161

COc1cc(OC)c(C(=O)[PH](=O)c2c(OC)cc(C(=O)c3ccccc3)c(OC)c2OC)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.43
▸ LMNA P02545 4/20 0.43
▸ HTT P42858 3/20 0.43
▸ MAPK1 P28482 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ PGR P06401 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ PDE4A P27815 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HRH1 P35367 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188996 0.92 MAPT (0.44) MAPTLMNAHTTMAPK1HPGD
SCHEMBL7188320 0.87 MAPT (0.42) MAPTLMNAHTTMAPK1HPGD
SCHEMBL7179526 0.86 TP53 (0.42) MAPTLMNAHTTMAPK1HPGD
SCHEMBL7186768 0.86 MAPT (0.41) MAPTLMNAMAPK1HPGDKDM4E
SCHEMBL7179738 0.85 HPGD (0.41) MAPTLMNAHTTMAPK1HPGD
SCHEMBL7189610 0.84 MAPT (0.40) MAPTLMNAHTTMAPK1HPGD
SCHEMBL7182523 0.84 MAPT (0.42) MAPTLMNAMAPK1HPGDKDM4E
SCHEMBL7174594 0.84 ABCG2 (0.40) MAPTLMNAHTTMAPK1HPGD
SCHEMBL7183284 0.84 MAPT (0.41) MAPTLMNAHTTMAPK1HPGD
SCHEMBL7190266 0.84 MAPT (0.39) MAPTLMNAHTTMAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885LMNA 3241/4885HTT 2802/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885LMNA 3247/4885HTT 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.